Latest News on STAA

Financial News Based On Company


Advertisement
Advertisement

Steven A. Cohen reports 819,979 STAAR Surgical (STAA) shares alongside two Point72 entities.

https://www.stocktitan.net/sec-filings/STAA/schedule-13g-a-staar-surgical-co-amended-passive-investment-disclosur-e5de94954d94.html
Steven A. Cohen, Point72 Asset Management, L.P., and Point72 Capital Advisors, Inc. have filed an amended passive investment disclosure (SCHEDULE 13G/A) for STAAR Surgical Company (STAA). Each reporting person disclosed beneficial ownership of 819,979 shares, representing 1.6% of the class, as of September 30, 2026. This report indicates a shared position rather than three separate holdings, with Point72 Asset Management managing the investment fund and Mr. Cohen controlling both Point72 entities.

One investor reports a 4.89 million-share stake in STAAR Surgical (STAA).

https://www.stocktitan.net/sec-filings/STAA/schedule-13g-a-staar-surgical-co-amended-passive-investment-disclosur-9daefb3b2641.html
Madison Avenue International LP has reported a beneficial ownership of 4,891,995 shares in STAAR Surgical Co (STAA) as of September 30, 2026. This stake represents approximately 9.7% of the company's common stock, based on 50,201,819 shares outstanding as of October 30, 2026. Several entities and an individual, including Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha, are deemed beneficial owners through their relationships.

SNU Eye Clinic's Dr. Chung Eui Sang Recognized at 2026 Korea & Japan ICL Forum

https://www.einpresswire.com/article/956991647/snu-eye-clinic-s-dr-chung-eui-sang-recognized-at-2026-korea-japan-icl-forum
Dr. Chung Eui Sang of SNU Eye Clinic was recognized at the 2026 Korea & Japan ICL Forum for his significant contributions to the advancement of EVO ICL and his extensive clinical experience in ICL surgery. He received an Appreciation Award from STAAR Surgical and shared his expertise with ophthalmologists from Korea and Japan, emphasizing the importance of precise examinations for ICL surgery. Dr. Chung has surpassed 10,000 EVO ICL procedures and continues to contribute to international academic exchange and clinical research in vision correction.

STAAR Surgical (STAA) Returns To Profit, Is The Stock Still Cheap?

https://simplywall.st/stocks/us/healthcare/nasdaq-staa/staar-surgical/news/staar-surgical-staa-returns-to-profit-is-the-stock-still-che
STAAR Surgical (STAA) recently reported its Q3 and nine-month 2026 results, returning to profit year-to-date despite a quarterly decline in sales and earnings compared to the previous year. The stock currently trades at US$26.39, below analyst targets and intrinsic value estimates, suggesting it might be undervalued. The company's future success hinges on converting its strong position in China and rising ex-China EVO adoption into market share gains, alongside effective operating expense management and successful manufacturing ramp-up in Nidau, Switzerland.

How (STAA) Movements Inform Risk Allocation Models

https://news.stocktradersdaily.com/news_release/141/How_STAA_Movements_Inform_Risk_Allocation_Models_111326060201_1794610921.html
This article analyzes Staar Surgical Company (NASDAQ: STAA) using AI models to inform risk allocation. It highlights conflicting sentiment across different time horizons, suggesting choppy market conditions, and identifies an exceptional risk-reward setup targeting a 22.8% gain with minimal risk. The report provides three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for varying risk profiles.
Advertisement

STAAR Surgical at Stifel 2026 Healthcare Conference: China gains, margin reset

https://ca.investing.com/news/stock-market-news/staar-surgical-at-stifel-2026-healthcare-conference-china-gains-margin-reset-93CH-4947282
STAAR Surgical presented at the Stifel 2026 Healthcare Conference, highlighting significant improvements in its China business with ICL shipments growing by 12.5% year-to-date through Q3. The company is also addressing manufacturing and margin pressures by shifting China-destined production to Switzerland, which is expected to reduce tariffs and improve gross margins. Despite rising competition and a "substantially undervalued" stock price, STAAR Surgical remains confident in its long-term growth driven by product mix, international expansion, and the superior biocompatibility of its Collamer material.

STAAR Surgical Company (STAA) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/STAA/seasonality/
The Yahoo Finance page for STAAR Surgical Company (STAA) displays its stock performance, showing a decrease of 1.94% in after-hours trading on November 6. The article focuses on historical seasonality, presenting average monthly price returns from 2016 to 2026. However, the core content of the article seems to be missing, replaced by an error message.

STAAR Surgical (STAA) Stock May Be 14% Undervalued On Cash Flow

https://simplywall.st/stocks/us/healthcare/nasdaq-staa/staar-surgical/news/staar-surgical-staa-stock-may-be-14-undervalued-on-cash-flow
STAAR Surgical's stock, trading at $25.21, may be 14% undervalued based on a Discounted Cash Flow (DCF) model, which projects growing annual free cash flows over the next decade from its current $9 million. While a bull case suggests a 10% undervaluation due to upcoming tariff removals, a bear case indicates a 33% overvaluation due to legal uncertainties. Investors are encouraged to consider the company's leadership and the assumptions underlying these cash flow projections.

Stifel raises STAAR Surgical stock price target on China demand

https://www.investing.com/news/analyst-ratings/stifel-raises-staar-surgical-stock-price-target-on-china-demand-93CH-5002653
Stifel increased its price target for STAAR Surgical (NASDAQ:STAA) to $34 from $31, maintaining a Buy rating, due to strong third-quarter 2026 results driven by EVO+ pricing and growth in China and other markets. The company exceeded revenue expectations and is benefiting from increased demand for its ICL volumes in China, outpacing supply. STAAR Surgical also reported impressive adjusted earnings and is advancing with next-generation presbyopia lenses trials while working to enhance manufacturing capacity.

STAAR Surgical Misses On Earnings As Margin Squeeze And Supply Limits Offset Accelerating Demand

https://finviz.com/news/416447/staar-surgical-misses-on-earnings-as-margin-squeeze-and-supply-limits-offset-accelerating-demand
STAAR Surgical (NASDAQ: STAA) reported third-quarter earnings that missed consensus and its own Whisper number, despite revenue beating expectations. The company faced a margin squeeze due to high unit costs, freight, tariffs, and inventory provisions, but saw accelerating demand, particularly in China and other international markets. However, supply constraints prevented STAAR from meeting lens demand, indicating that while the demand story improved, profit recovery is delayed, with future performance dependent on execution and increased capacity.
Advertisement

STAAR Surgical (NASDAQ:STAA) reports strong Q3 2026

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-4-staar-surgical-nasdaqstaa-reports-strong-q3-2026
STAAR Surgical (NASDAQ:STAA) reported strong Q3 2026 results, surpassing revenue expectations with $83.41 million, despite a 12% year-on-year decline. The company also significantly beat GAAP profit estimates with $0.11 per share. Despite recent revenue declines, analysts expect a 9.5% growth in the next 12 months, driven by new products, and a substantial increase in full-year EPS.

STAAR Surgical (NASDAQ:STAA) reports strong Q3 2026

http://markets.chroniclejournal.com/chroniclejournal/article/stockstory-2026-11-4-staar-surgical-nasdaqstaa-reports-strong-q3-2026
STAAR Surgical (NASDAQ: STAA) reported Q3 2026 results that exceeded revenue and GAAP profit expectations, with revenue of $83.41 million, despite a 12% year-on-year decline. The company posted a GAAP profit of $0.11 per share, significantly above analyst estimates. Despite recent revenue declines, analysts project a 9.5% revenue growth for the next 12 months, and a substantial increase in full-year EPS.

Avoiding Lag: Real-Time Signals in (STAA) Movement

https://news.stocktradersdaily.com/news_release/11/Avoiding_Lag:_Real-Time_Signals_in_STAA_Movement_110326061802_1793747882.html
Staar Surgical Company (NASDAQ: STAA) is showing strong near and mid-term sentiment, with an exceptional 78.7:1 risk-reward setup targeting a 22.4% gain. AI models have generated three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis highlights key support and resistance levels across multiple time horizons, with positive sentiment currently prevailing.

Earnings to watch: STAAR Surgical (STAA) reports Q3 results tomorrow

https://stockstory.org/us/stocks/nasdaq/staa/news/earnings/earnings-to-watch-staar-surgical-staa-reports-q3-results-tomorrow
STAAR Surgical (NASDAQ:STAA) is set to report its Q3 results on Wednesday after the bell. The medical lens company previously beat analysts' revenue expectations in the last quarter, reporting $93.54 million, up 111% year over year. However, for the upcoming quarter, the market anticipates a 17.5% year-on-year revenue decline.

STAAR Surgical (STAA) Faces A Fresh Asia Pacific Test As Fair Value Stays In Focus

https://simplywall.st/stocks/us/healthcare/nasdaq-staa/staar-surgical/news/staar-surgical-staa-faces-a-fresh-asia-pacific-test-as-fair
STAAR Surgical has appointed Pascal Aeschlimann as Vice President of Asia Pacific to oversee commercial activity outside China, aiming to capitalize on rising demand for vision correction. Despite short-term share price climbs, longer-term returns have been weak, but analysts still see the stock as modestly undervalued at $28 against a closing price of $24.56, contingent on strong execution in market share gains and managing operating expenses. However, a higher price-to-sales multiple compared to peers suggests less room for error if growth or margins disappoint.
Advertisement

STAAR Surgical Company (STAA) Seasonal returns chart - Yahoo Finance

https://sg.finance.yahoo.com/quote/STAA/seasonality/
This article from Yahoo Finance provides a seasonal returns chart for STAAR Surgical Company (STAA), displaying average monthly price returns from 2016 to 2026. It also includes current stock information, showing STAA's real-time price and after-hours trading activity, and announces the company's Q3 2026 earnings call.

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

https://www.visionmonday.com/eyecare/article/staar-surgical-appoints-pascal-aeschlimann-as-vice-president-of-asia-pacific/
STAAR Surgical Company has announced the appointment of Pascal Aeschlimann as vice president of Asia Pacific, effective November 2, 2026. Aeschlimann previously led STAAR's commercial expansion in Asia and the Middle East from 2002 to 2010 and returns after more than a decade building ophthalmic businesses in the region. Based in Singapore, he will lead STAAR's commercial business across the Asia Pacific region, excluding China, focusing on surgeon engagement, clinical education, and patient adoption.

Is STAAR Surgical (STAA) Cheap If Cash Flow Recovers?

https://simplywall.st/stocks/us/healthcare/nasdaq-staa/staar-surgical/news/is-staar-surgical-staa-cheap-if-cash-flow-recovers
STAAR Surgical's share price has significantly underperformed over the past five years, prompting an analysis of whether its current valuation aligns with its potential cash flow recovery. A Discounted Cash Flow (DCF) model suggests the stock could be modestly undervalued if it transitions from cash burn to consistent positive cash generation, though an ongoing investigation into fiduciary breaches introduces governance risk. Community narratives present both bull and bear cases, highlighting factors like global lens demand versus reliance on the Chinese market and governance concerns.

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

https://www.citybiz.co/article/926212/staar-surgical-appoints-pascal-aeschlimann-as-vice-president-of-asia-pacific/
STAAR Surgical (NASDAQ: STAA) has appointed Pascal Aeschlimann as Vice President of Asia Pacific, effective November 2, 2026. Aeschlimann, who previously worked at STAAR from 2002 to 2010, will lead commercial operations across the region, excluding China, focusing on expanding surgeon engagement and increasing adoption of the company's implantable lens-based vision correction products. His appointment is part of STAAR's strategy to strengthen regional leadership and capitalize on the growing Asia Pacific market for refractive vision correction.

STAAR Surgical names Pascal Aeschlimann Asia Pacific VP

https://www.investing.com/news/company-news/staar-surgical-names-pascal-aeschlimann-asia-pacific-vp-93CH-4982810
STAAR Surgical Company has appointed Pascal Aeschlimann as Vice President of Asia Pacific, effective November 2, 2026. Aeschlimann, who previously worked for STAAR from 2002 to 2010, will be based in Singapore and lead the company's commercial business across the Asia Pacific region, excluding China. This appointment aims to strengthen regional leadership and accelerate surgeon development and partnerships for vision correction.
Advertisement

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

https://finance.yahoo.com/healthcare/articles/staar-surgical-appoints-pascal-aeschlimann-110100465.html
STAAR Surgical Company has appointed Pascal Aeschlimann as Vice President of Asia Pacific, excluding China, effective November 2, 2026. Aeschlimann, who previously led STAAR's commercial expansion in Asia and the Middle East, returns to localize senior commercial leadership and capitalize on the region's significant growth in vision correction. His focus will be on deepening surgeon engagement, expanding clinical education, and increasing patient adoption of STAAR's EVO ICL™ products.

A former STAAR executive will return to lead its Asia-Pacific business outside China

https://www.stocktitan.net/news/STAA/staar-surgical-appoints-pascal-aeschlimann-as-vice-president-of-asia-dmbgaiczldfg.html
STAAR Surgical (NASDAQ: STAA) has appointed Pascal Aeschlimann as Vice President of Asia Pacific, excluding China, effective November 2, 2026. Aeschlimann previously led STAAR's commercial expansion in Asia and the Middle East from 2002 to 2010 and returns after building and leading ophthalmic businesses in the region for over a decade. His appointment aims to localize senior commercial leadership and strengthen execution in one of the fastest-growing vision correction markets.

Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline

https://finance.yahoo.com/markets/stocks/articles/earnings-preview-staar-surgical-staa-130017637.html
Staar Surgical (STAA) is projected to experience a year-over-year decline in both earnings and revenues for the quarter ending September 2026, with an expected EPS of $0.19, down 58.7%, and revenues of $81.53 million, a 13.9% decrease. Despite a 20% upward revision in the consensus EPS estimate over the last 30 days, the company's Zacks Earnings ESP of -12.07% combined with a Zacks Rank #1 makes it difficult to definitively predict an earnings beat. Investors should monitor the actual results, expected on November 4, as they could significantly impact the stock's near-term performance.

STAAR Surgical to Participate in Upcoming Investor Conferences

https://www.streetinsider.com/dr/news.php?id=27241003
STAAR Surgical Company announced that its President and CEO, Warren Foust, and Executive Vice President and CFO, Deborah Andrews, will participate in two investor conferences in November: the Stifel 2026 Healthcare Conference and the Canaccord Genuity MedTech, Diagnostics and Digital Health and Services Forum. They will be available for one-on-one meetings with institutional investors, and webcasts of their fireside chats will be available on the company's investor website.

STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026

https://finance.yahoo.com/healthcare/articles/staar-surgical-host-third-quarter-200100095.html
STAAR Surgical Company (NASDAQ: STAA) announced it will release its third-quarter 2026 financial results and a letter to shareholders on Wednesday, November 4, 2026, after market close. The company will also host an earnings call and webcast at 5:30 p.m. ET on the same day to discuss its financial performance and business advancements. Investors can pre-register for the live webcast or submit questions in advance via email.
Advertisement

STAAR Surgical Company Estimates – NASDAQ:STAA

https://www.tradingview.com/symbols/NASDAQ-STAA/financials-estimates/
This page on TradingView provides financial actuals and estimates for STAAR Surgical Company (NASDAQ: STAA). Users can explore reported financial data and analyst estimates across the income statement, balance sheet, cash flow statement, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform offers both annual and quarterly data for analysis.

STAAR Surgical to host Q3FY26 earnings call on November 4

https://scanx.trade/stock-market-news/companies/staar-surgical-host-q3fy26-earnings-call-november-4/54168712
STAAR Surgical will release its financial results for the third quarter ended October 2, 2026, on Wednesday, November 4, 2026, after market close. The company will host an earnings call and webcast at 5:30 pm ET on the same day to discuss its financial performance and business progress. Investors can access the live webcast via the company's investor relations section, with a replay available for at least 90 days.

STAAR Surgical sets Q3 2026 earnings call for Nov. 4 | STAA Stock News

https://www.stocktitan.net/news/STAA/staar-surgical-to-host-third-quarter-2026-earnings-results-call-and-eq39n60ps5wd.html
STAAR Surgical (NASDAQ: STAA) has announced that it will release its third-quarter 2026 financial results and a shareholder letter after market close on November 4, 2026. The company will also host an earnings call and webcast at 5:30 p.m. ET on the same day to discuss its financial performance and business progress. Investors can submit questions in advance via email.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)

https://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-notifies-shareholders-of-an-investigation-concerning-possible-breaches-of-fiduciary-duties-by-certain-officers-and-directors-of-staar-surgical-company-nasdaq-staa-302915856.html
Levi & Korsinsky, LLP has launched an investigation into STAAR Surgical Company (NASDAQ: STAA) concerning potential breaches of fiduciary duties by its officers and directors. Current shareholders are invited to request further information regarding this inquiry. The firm specializes in securities litigation and aims to recover losses for aggrieved investors.

STAAR Surgical names Andrew Pilon: Stifel target for STAAR Surgical stock is USD 31

https://www.ad-hoc-news.de/boerse/news/nebenwerte/staar-surgical-names-andrew-pilon-stifel-target-for-staar-surgical-stock-is-usd-31/70372701
STAAR Surgical has appointed Andrew Pilon as Vice President of Business Development, signaling a focus on strategic growth. This appointment follows a strong second quarter with revenue up 111.1% year-over-year. Stifel has maintained a "Buy" rating and a USD 31 price target for STAAR Surgical stock, driven by expectations of growth in China and an improved product mix.
Advertisement

STAAR Surgical names Andrew Pilon. Stifel targets STAAR Surgical stock at USD 31

https://www.ad-hoc-news.de/boerse/news/nebenwerte/staar-surgical-names-andrew-pilon-stifel-targets-staar-surgical-stock-at-usd-31/70353648
STAAR Surgical has appointed Andrew Pilon as vice president of business development. Stifel raised its price target for STAAR Surgical stock to USD 31, citing strong second-quarter revenue of USD 93.5 million. The company recently authorized a USD 50 million share repurchase program, and its next earnings report is expected on November 4, 2026.

STAAR Surgical names Andrew Pilon. Stifel targets STAAR Surgical stock at USD 31

https://www.ad-hoc-news.de/boerse/news/nebenwerte/staar-surgical-names-andrew-pilon-stifel-targets-staar-surgical-stock-at/70353648
STAAR Surgical has appointed Andrew Pilon as Vice President of Business Development. Stifel has raised its price target for STAAR Surgical stock to $31, following a Q2 2026 revenue beat of $93.5 million. The company's market capitalization stands at $1.1 billion, and it is set to report its third-quarter 2026 results on November 4.

STAAR Surgical Company (STAA) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_5962_QuantitativeReport_1765929600000/
This article provides a stock forecast for STAAR Surgical Company (STAA), mentioning that Argus has lowered its target price to $26.00. STAAR Surgical is described as a manufacturer of implantable lenses for the eye. The report also highlights other related market updates and company reports.

Stifel raises target for STAAR Surgical stock from USD 28 to USD 31

https://www.ad-hoc-news.de/boerse/news/nebenwerte/stifel-raises-target-for-staar-surgical-stock-from-usd-28-to-usd-31/70328888
Stifel has raised its price target for STAAR Surgical (STAA) stock from USD 28 to USD 31, citing stronger international sales momentum and potential recovery in China. This follows STAAR Surgical's strong second-quarter 2026 performance, which saw revenue increase by 111.1% to USD 93.53 million and a return to profitability with net income of USD 8.06 million. The company also recently authorized a USD 50 million share repurchase program and appointed a new vice president of business development.

How Analyst Upgrade Will Impact STAAR Surgical Stock (STAA)

https://simplywall.st/stocks/us/healthcare/nasdaq-staa/staar-surgical/news/how-analyst-upgrade-will-impact-staar-surgical-stock-staa
STAAR Surgical has appointed a new VP of business development to boost its implantable lens portfolio amidst flat revenue and weaker returns. The company's investment narrative is now shaped by a new US$50 million share buyback and improving international sales, with analysts projecting significant revenue and earnings growth by 2029. Despite potential upside, concerns remain regarding execution on manufacturing, China demand, and governance risks.
Advertisement

3 Reasons STAA is Risky and 1 Stock to Buy Instead

https://www.theglobeandmail.com/investing/markets/stocks/STAA/pressreleases/6160413/3-reasons-staa-is-risky-and-1-stock-to-buy-instead/
This article identifies STAAR Surgical (STAA) as a risky investment due to flatlining revenue growth, limited distribution channels, and declining return on invested capital (ROIC). Despite a recent stock price drop, the authors advise against buying STAA, suggesting its current valuation already prices in too much good news. Instead, they recommend looking into their top digital advertising picks and other high-growth stocks identified by their AI.

STAAR Surgical (STAA) Stock Could Be Cheap As Shares Fell 82%

https://simplywall.st/stocks/us/healthcare/nasdaq-staa/staar-surgical/news/staar-surgical-staa-stock-could-be-cheap-as-shares-fell-82
STAAR Surgical's share price has dropped 81.6% over the last five years despite management highlighting new hires and product expansion, prompting questions about its current valuation. A Discounted Cash Flow (DCF) model suggests the company is undervalued, as it projects a shift from negative to positive free cash flow, placing its intrinsic value above the current share price of $21.67. While some narratives view the stock as 23% undervalued due to its strong position in China and EVO adoption, bearish analysts see it as 14% overvalued, citing heavy exposure to a single refractive lens franchise and potential risks to growth.

STAAR Surgical Appoints Andrew Pilon, OD, as Vice President of Business Development

https://www.visionmonday.com/people/moves/article/staar-surgical-appoints-andrew-pilon-od-as-vice-president-of-business-development/
STAAR Surgical Co. (NASDAQ: STAA) has appointed Andrew Pilon, OD, as its new vice president of business development. Dr. Pilon, who previously held a senior director role at Johnson & Johnson Vision, will focus on strategic partnerships, acquisitions, and licensing opportunities to expand STAAR Surgical's product portfolio and innovation strategy. His appointment is expected to help accelerate innovation and broaden the company's offerings to patients and physicians.

3 Reasons STAA is Risky and 1 Stock to Buy Instead

https://stockstory.org/us/stocks/nasdaq/staa/news/buy-or-sell/3-reasons-staa-is-risky-and-1-stock-to-buy-instead
STAAR Surgical (STAA) has underperformed the S&P 500 significantly, posting a 19.9% loss over the past six months. StockStory analysts identify three main risks: flatlining revenue growth, limited distribution channels due to its small size in a scale-driven industry, and declining return on invested capital (ROIC). The article concludes that STAA trades at a high forward P/E multiple despite these issues and suggests looking into other growth stocks.

STAAR Surgical Company (STAA) stock price, news, quote and history

https://au.finance.yahoo.com/quote/STAA/
This Yahoo Finance page provides comprehensive information on STAAR Surgical Company (STAA) stock, including its current price, historical data, and key financial metrics. It details the company's overview, its products like implantable collamer lenses for visual disorders, and its global market presence. The page also includes performance overviews, earnings trends, analyst insights with price targets and recommendations, and various valuation measures.
Advertisement

STAAR Surgical (STAA) Posted A Standout Quarter, Is The Stock Cheap Enough?

https://simplywall.st/stocks/us/healthcare/nasdaq-staa/staar-surgical/news/staar-surgical-staa-posted-a-standout-quarter-is-the-stock-c/amp
STAAR Surgical (STAA) reported a strong quarter with 111% year-on-year revenue growth, exceeding analyst expectations, yet its stock price has declined significantly. The company is considered 20% undervalued with a fair value of $28, despite trading at a higher sales multiple than its industry peers. The article explores the mixed signals regarding STAA's valuation and suggests further investigation into potential upsides and risks.

Winners And Losers Of Q2: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks

https://www.theglobeandmail.com/investing/markets/stocks/STAA-Q/pressreleases/5075646/winners-and-losers-of-q2-staar-surgical-nasdaqstaa-vs-the-rest-of-the-medical-devices-supplies-specialty-stocks/
This article analyzes the Q2 performance of several medical devices and supplies companies, highlighting STAAR Surgical (STAA) as having the biggest analyst estimate beat and fastest revenue growth, despite a subsequent stock dip. Inspire Medical Systems (INSP) achieved the highest full-year guidance raise, while Enovis (ENOV) was the weakest performer against analyst estimates. The piece also discusses the broader industry trends, including demographic tailwinds and ongoing challenges from pricing pressures and regulatory complexities.

STAAR Surgical names Andrew Pilon as VP of business development

https://www.investing.com/news/company-news/staar-surgical-names-andrew-pilon-as-vp-of-business-development-93CH-4939653
STAAR Surgical Company has appointed Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will be instrumental in the company's innovation strategy and product portfolio expansion, reporting directly to the President and CEO. He brings extensive experience from Johnson & Johnson Vision and Bausch + Lomb, alongside a background as a practicing optometrist and clinical faculty member.

STAAR Surgical names Andrew Pilon as VP of business development By Investing.com

https://ca.investing.com/news/stock-market-news/staar-surgical-names-andrew-pilon-as-vp-of-business-development-93CH-4872341
STAAR Surgical Company has appointed Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon previously served as Senior Director of Business Development for Johnson & Johnson Vision's Surgical Vision division and held leadership roles at Bausch + Lomb. He will report to CEO Warren Foust and focus on innovation strategy and product portfolio expansion for STAAR Surgical.

A Johnson & Johnson Vision executive is joining STAAR Surgical to help build partnerships.

https://www.stocktitan.net/news/STAA/staar-surgical-names-andrew-pilon-as-vice-president-of-business-jb4wowgok1aa.html
STAAR Surgical has appointed Andrew Pilon, O.D. as Vice President of Business Development to enhance its innovation strategy and expand its product portfolio. Dr. Pilon previously served as Senior Director of Business Development for Johnson & Johnson Vision, bringing extensive experience in strategic partnerships, acquisitions, and licensing. His role will focus on identifying new opportunities and strengthening STAAR's capabilities, particularly with its EVO ICL technology.
Advertisement

Staar Surgical appoints Andrew Pilon as VP of business development

https://www.streetinsider.com/Management+Changes/Staar+Surgical+appoints+Andrew+Pilon+as+VP+of+business+development/27166735.html
Staar Surgical has appointed Andrew Pilon, O.D., as Vice President of Business Development. Dr. Pilon previously held senior roles at Johnson & Johnson Vision and Bausch + Lomb, bringing extensive ophthalmology experience and a strong background in strategic growth and clinical expertise to Staar Surgical. He will report to President and CEO Warren Foust.

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

https://www.financialcontent.com/article/bizwire-2026-10-8-staar-surgical-names-andrew-pilon-as-vice-president-of-business-development
STAAR Surgical has appointed Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon, formerly of Johnson & Johnson Vision, will focus on advancing STAAR's strategic partnerships, innovation opportunities, and expanding its product portfolio. His extensive experience in ophthalmology and strategic growth is expected to help accelerate innovation and broaden the company's offerings.

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

https://finance.yahoo.com/healthcare/articles/staar-surgical-names-andrew-pilon-191400023.html
STAAR Surgical Company has appointed Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon, formerly of Johnson & Johnson Vision, will report to CEO Warren Foust and focus on advancing STAAR's strategic partnerships, innovation opportunities, and expanding its multi-product platform. His expertise in clinical ophthalmology and strategic growth is expected to help the company grow its EVO ICL product and pursue new technologies.

Equity awards remain 50% stock grants, 50% options in STAAR Surgical (STAA)'s corrected Bailey pay disclosure.

https://www.stocktitan.net/sec-filings/STAA/8-k-a-staar-surgical-co-amends-material-event-report-8d623abb49e8.html
STAAR Surgical (STAA) filed an amended 8-K to correct the allocation of equity awards for its Chief Commercial Officer, David Bailey, ensuring it matches his offer letter. While the dollar values of his initial $850,000 equity grant and $1,400,000 long-term incentive award remain correct, the correction clarifies that both are split evenly between restricted stock units (RSUs) and stock options. Bailey's total compensation package also includes an annual base salary of CHF 462,825 (approximately $575,000) and a fiscal 2026 cash bonus target of 60% of his base salary, all prorated based on his September 8, 2026, start date.

Stifel raises target for STAAR Surgical stock to USD 31.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/stifel-raises-target-for-staar-surgical-stock-to-usd-31-00/70214670
Stifel has upgraded STAAR Surgical (STAA) from Hold to Buy and increased its price target from USD 28.00 to USD 31.00 following strong second-quarter 2026 revenue and EPS results. The company also announced a USD 50.00 million share repurchase authorization. Stifel's positive outlook is based on anticipated sales of higher-priced EVO+ implantable Collamer lenses in China and easier international comparisons in the latter half of 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement